Visfatin and endothelial function in dialyzed patients

Nephrology

Volumn 15, Issue 2, 2010, Pages 190-196

  Malyszko, Jolanta ^a   Malyszko, Jacek S ^a   Mysliwiec, Michal ^a  

^a Medical University   (Poland)

Author keywords

Haemodialysis; Inflammation; Peritoneal dialyses; Visfatin

Indexed keywords

ADIPONECTIN; APELIN; C REACTIVE PROTEIN; CD146 ANTIGEN; GLYCOPROTEIN VI; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; CELL DAMAGE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; ENDOTHELIUM INJURY; FIBRINOLYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PATIENT; PERITONEAL DIALYSIS PATIENT; PRIORITY JOURNAL;

ADIPOKINES; ADULT; AGED; BIOLOGICAL MARKERS; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY DISEASES; LINEAR MODELS; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION;

EID: 77749302225     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01180.x     Document Type: Article

References (37)

1. Lindner A, Charra B, Sherrad DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N. Engl. J. Med. 1974 290 : 697 701.
2. Bloembergen WE, Prot FK, Mauger EA, Wolfe RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J. Am. Soc. Nephrol. 1995 6 : 184 191.
3. Kawaguchi Y, Kubo H, Yamamoto H, Nakayama K, Shigematsu T, Sakai O. Is atherosclerosis accelerated by CAPD? Perit. Dial. Int. 1996 16 (Suppl 1 S23 S30.
4. Zhang Y, Proenca R, Maffei M, Barone M, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994 372 : 425 432.
5. Halaas JL, Gajiwala KS, Maffei M et al. Weight-reducing effects of the plasma proteins encoded by the obese genes. Science 1995 269 : 543 546.
6. Hotamisligil GS. The role of TNFα and TNF receptors in obesity and insulin resistance. J. Intern. Med. 1999 245 : 621 625.
7. Shimomura I, Funahashi T, Takahashi M et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat. Med. 1996 2 : 800 803.
8. Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostasis between CAPD and HD patients. Perit. Dial. Int. 2001 21 : 158 165.
9. Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1997 76 : 56 61.
10. Malyszko J, Wolczynski S, Malyszko J, Mysliwiec M. Leptin correlates with some hemostatic parameters in CAPD patients. Nephron 2002 92 : 721 724.
11. Malyszko J, Malyszko JS, Wolczynski S, Brzosko S, Mysliwiec M. Markers of endothelial cell activation/injury: CD146 and thrombomodulin, are related to adiponectin in kidney allograft recipients. Am. J. Nephrol. 2005 25 : 203 210.
12. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005 307 : 426 430. (Pubitemid 40139988)
13. Yilmaz MI, Saglam M, Carrero JJ et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol. Dial. Transplant. 2008 23 : 959 965. (Pubitemid 351767576)
14. Axelsson J, Witasp A, Carrero JJ et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am. J. Kidney Dis. 2007 49 : 237 244.
15. Bardin N, Moal V, Anfosso F et al. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb. Hemost. 2003 90 : 915 920.
16. Malyszko J, Malyszko JS, Wolczynski S, Brzosko S, Mysliwiec M. Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J. Clin. Endocrinol. Metab. 2004 89 : 4620 4627.
17. Malyszko J, Malyszko JS, Kozminski P, Pawlak K, Mysliwiec M. Adipokines, linking adipocytes and vascular function in hemodialyzed patients, may also be possibly related to CD146, a novel adhesion molecule. Clin. Appl. Thromb. Hemost. 2008 14 : 338 345.
18. Malyszko J, Malyszko JS, Kozminski P, Pawlak K, Mysliwiec M. Elevated resistin is related to inflammation and residual renal function in hemodialyzed patients. Nephrology 2007 12 : 246 253.
19. Chen MP, Chung FM, Chang DM et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2006 91 : 295 299.
20. Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J. Clin. Endocrinol. Metab. 2006 91 : 1181 1184.
21. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell Biol. 1994 14 : 1431 1437.
22. Müller WE, Perovic S, Wilkesman J, Kruse M, Müller IM, Batel R. Increased gene expression of a cytokine-related molecule and profilin after activation of Suberites domuncula cells with xenogeneic sponge molecule(s). DNA Cell Biol. 1999 18 : 885 893.
23. Jia SH, Li Y, Parodo J et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J. Clin. Invest. 2004 113 : 1318 1327.
24. Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am. J. Obstet. Gynecol. 2002 187 : 1051 1058.
25. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007 178 : 1748 1758.
26. Kralisch S, Klein J, Lossner U et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am. J. Physiol Endocrinol Metab. 2005 289 : E586 90.
27. Fasshauer M, Waldeyer T, Seeger J et al. Serum levels of the adipokine visfatin are increased in preeclampsia. Clin. Endocrinol. (Oxf.) 2007 69 : 69 73.
28. Seo JA, Jang ES, Kim BG et al. Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Res. Clin. Pract. 2008 79 : 108 111.
29. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin. Endocrinol. (Oxf.) 2007 67 : 796 800.
30. Erten Y, Ebinç FA, Ebinç H et al. The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren. Fail. 2008 30 : 617 623.
31. Kato A, Odamaki M, Ishida J, Hishida A. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am. J. Nephrol. 2008 29 : 31 5.
32. Ziegelmeier M, Bachmann A, Seeger J et al. Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis. Metabolism 2008 57 : 1414 1421.
33. Fernández-Real JM, Moreno JM, Chico B, López-Bermejo A, Ricart W. Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. Diabetes Care 2007 30 : 616 621.
34. Fleming RE, Sly WS. Hepcidin: A putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc. Natl Acad. Sci. USA 2001 98 : 8160 8162.
35. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003 101 : 2461 2463. (Pubitemid 36857598)
36. Bekri S, Gual P, Anty R et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006 131 : 788 796.
37. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev. 2007 18 : 313 325. (Pubitemid 46891288)